Heat Biologics Inc. (HTBX) Given $5.38 Average Target Price by Analysts
Shares of Heat Biologics Inc. (NASDAQ:HTBX) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price objective of $5.38 for the company and are forecasting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 108 out of 265 based on the ratings given to related companies.
Several analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Heat Biologics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Friday, August 19th. Roth Capital reiterated a “buy” rating and set a $2.75 target price on shares of Heat Biologics in a research report on Thursday, September 15th. Finally, Noble Financial reiterated a “buy” rating and set a $8.00 target price on shares of Heat Biologics in a research report on Wednesday, August 17th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/heat-biologics-inc-htbx-given-5-38-average-target-price-by-analysts.html
A hedge fund recently raised its stake in Heat Biologics stock. Sabby Management LLC raised its stake in shares of Heat Biologics Inc. (NASDAQ:HTBX) by 4,005.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 902,007 shares of the biopharmaceutical company’s stock after buying an additional 880,036 shares during the period. Sabby Management LLC owned about 10.71% of Heat Biologics worth $626,000 as of its most recent filing with the SEC. Institutional investors own 8.62% of the company’s stock.
Shares of Heat Biologics (NASDAQ:HTBX) traded down 1.69% during mid-day trading on Tuesday, reaching $1.16. The company had a trading volume of 150,847 shares. Heat Biologics has a 52-week low of $0.40 and a 52-week high of $4.98. The stock’s market capitalization is $22.61 million. The company’s 50-day moving average is $1.35 and its 200 day moving average is $0.95.
Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.10. Analysts anticipate that Heat Biologics will post ($0.76) EPS for the current fiscal year.
About Heat Biologics
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.